Astek Diagnostics

Presenting Astek, dedicated to saving lives through precision diagnostics in antibiotic sensitivity.

Our proactive delivery roadmap is set with pivotal timelines leading to FDA approval by 2025.

Astek aims for the Jiddu system to revolutionize diagnostics across various sample types.

The comprehensive Jiddu system offers a robust approach to diagnosing infections and antibiotic sensitivity with a proven 97% accuracy in urine-based tests.

UTIs pose significant health and economic burdens due to outdated diagnostics and improper antibiotic prescriptions, exacerbating antimicrobial resistance.

The Jiddu system delivers rapid, accurate UTI detection and antibiotic sensitivity results within an hour, improving patient care and reducing costs.

Our technology is designed for ease of use, capturing bacteria efficiently and providing reliable results by measuring metabolic activity and antibiotic efficiency.

Astek is propelled by a skilled core team and esteemed advisory board, bringing extensive industry experience and expertise.

The Jiddu system has demonstrated high accuracy in pilots; we have strong partnerships and significant funding from investors and grants.

Our technology is well-protected with issued and pending patents covering key innovations in diagnostics and sample processing.

Our timeline outlines critical milestones from initial pilots to clinical trials and market launch.

We seek $XX million via convertible notes to achieve our next phase targets, with compelling terms for investors including tax incentives.

Our commercialization strategy focuses on outsourcing production while planning an exit through potential acquisition upon FDA clearance.

Comparable successful transactions in the diagnostics market illustrate Astek's potential for high market valuation and acquisition interest.

We have built and validated a highly accurate platform and are now pursuing $XXM to complete development and clinical trials.